AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS| Amgen
Amgen (AMGN) responded to the FTC's complaint seeking to block its proposed acquisition of Horizon Therapeutics. Amgen expressed disappointment and commitment to completing the deal, which it believes will benefit patients with rare diseases. The company argues that the acquisition poses no competitive issues and plans to work with the court to close the transaction by mid-December.
How this was made
The 30-second read
Why it matters
Regulatory opposition introduces significant deal risk, likely weighing on both stocks until the case is resolved.
Market read
The FTC challenge adds regulatory risk to a high‑profile biotech merger, influencing investor sentiment in the sector.
What to watch
Potential concessions or divestitures could satisfy regulators and keep the deal alive.
Background
Amgen announced a planned acquisition of Horizon Therapeutics, which the FTC has now challenged on antitrust grounds.
Ticker impact
Amgen issued a statement responding to the FTC complaint seeking to block its proposed acquisition of Horizon Therapeutics.
likely downward pressure as investors price in potential delay or cancellation of the acquisition
Regulatory opposition to a large‑cap biotech merger typically depresses the target's and acquirer's stock until resolution.
Market effects
The biotech M&A landscape may see heightened scrutiny, affecting other pending deals.
U.S. biotech stocks could experience broader volatility as regulators signal tougher oversight.
International investors in Amgen and Horizon may adjust exposure pending regulatory outcome.
Counterpoint
If the FTC's case is weak, the market may overreact, presenting a buying opportunity on a resolution.
Key entities
- CompanyAmgen
US biotech giant proposing the acquisition.
- CompanyHorizon Therapeutics
Target of the proposed acquisition.
- RegulatorFederal Trade Commission
U.S. antitrust agency filing the complaint.
